Josh Mandel-Brehm compensation by year
Camp4 Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $557,250 | $600,000 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $404,991 | $2,430,988 |
| Non-equity incentive | $201,000 | $285,750 |
| Pension and deferred compensation | $0 | $0 |
| All other | $1,131,744 | $10,500 |
| Total | $2,294,985 | $3,327,238 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Camp4 Therapeutics Corp DEF 14A filed April 23, 2026, accession 0001736730-26-000026, and prior-year filings.
How this page was built: the Camp4 Therapeutics Corp filed document, accession 0001736730-26-000026. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 6,060 | $10,000 | — |
| Option | 4,179 | — | $5.50 |
| Option | 425,000 | — | $6.01 |
| Option | 64,061 | — | $8.41 |
| Option | 25,071 | — | $9.08 |
| Option | 130,001 | — | $3.86 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Camp4 Therapeutics Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 23, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-03 | Purchase | — | 6,551 | $1.65 | 284,968 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Camp4 Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Josh Mandel-Brehm · this page | President and Chief Executive Officer | $3,327,238 |
| Kelly Gold | Chief Financial Officer | $1,846,733 |
| Yuri Maricich | Chief Medical Officer | $1,814,042 |
Board service
Camp4 Therapeutics board · FY2025How this board is paid
Company policy: Camp4 Therapeutics pays directors a $40,000 cash retainer. As stated in Camp4 Therapeutics's FY2025 proxy.
The full Camp4 Therapeutics compensation record
free company briefThis page is one person within Camp4 Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Camp4 Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Camp4 Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.